- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06129175
UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)
Cytopeutics® A Phase II-III Double-Blind Randomized Controlled Study to Assess the Efficacy of Umbilical Cord Mesenchymal Stem Cells (Neuroncell-EX) Transplantation in Patients With Acute Ischemic Stroke
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Ischemic stroke is a serious cerebrovascular disease with high morbidity and disability worldwide. Despite the great efforts that have been made, the prognosis of stroke patients remains unsatisfactory. Mesenchymal stem cells (MSCs) therapy is an emerging treatment studied in various medical conditions including autoimmune, inflammatory as well as central nervous system diseases. The mechanism of MSCs in the treatment of ischemic stroke involved with immune regulation, neuroprotection, angiogenesis, and neural circuit reconstruction. A large number of preclinical data have proved the feasibility of MSCs in the treatment of stroke where the administration of MSCs can alleviate neurological deficits. Similarly, a number of clinical trials have also proved the effectiveness and safety of MSCs in the treatment of stroke. Among these is a phase 2, single-center, assessor-blinded randomized controlled study by investigators using bone marrow-derived MSCs in patients with subacute middle cerebral artery infarct. The investigators demonstrated the safety, tolerability, and efficacy of intravenous infusion of MSCs with significant improvement in median infarct volume (Law et al., 2021).
Objective: To determine the efficacy of intravenous infusion of allogeneic Cytopeutics umbilical cord mesenchymal stem cells (Neuroncell-EX) in participants with acute ischemic stroke.
Study Design: This is a phase II-III double-blind randomized controlled study involving 80 participants, diagnosed with acute ischemic stroke admitted to HCTM-UKM. Investigational treatment arm (Group A-MSCs) consist of 40 participants will receive Neuroncell-EX whereas control treatment arm (Group B-Control) consist of 40 participants will receive placebo. Both groups will also receive standard medical care for acute stroke. Efficacy assessments will include Barthel index (BI) and modified Rankin Scale (mRS), Functional Magnetic Resonance Imaging (fMRI) and blood tests including biomarkers within 12 months follow-up.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Sze Piaw Chin
- Phone Number: +603-8688 1098
- Email: operation@cytopeutics.com
Study Contact Backup
- Name: Nik Syazana Saffery
- Phone Number: +6016-2192675
- Email: niksyazana@cytopeutics.com
Study Locations
-
-
Wilayah Persekutuan Kuala Lumpur
-
Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia, 56000
- Recruiting
- Hospital Canselor Tuanku Muhriz UKM
-
Contact:
- Wan Nur Nafisah Wan Yahya
- Phone Number: +603-91455798
- Email: nafisahyahya@gmail.com
-
Contact:
- Siti Zaleha Sahibulddin
- Email: zazz_lea21@yahoo.com
-
Sub-Investigator:
- Norlinah Mohamed Ibrahim
-
Sub-Investigator:
- Hui Jan Tan
-
Sub-Investigator:
- Zhe Kang Law
-
Sub-Investigator:
- Wan Asyraf Wan Zaidi
-
Sub-Investigator:
- Ching Soong Khoo
-
Sub-Investigator:
- S Fadilah Abdul Wahid
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must be aged ≥ 18 years old.
- Patients with acute ischemic stroke symptom onset within 4 weeks.
- Patients diagnosed with "moderate to severe" based on NIHSS (6-24) at the time of recruitment.
- Patients who are not eligible for thrombolysis or thrombectomy.
- Written informed consent by the patient or next-of-kin.
Exclusion Criteria:
- Patients who are medically unfit such as those who are haemodynamically unstable or whose general condition is deteriorating.
- Patients with transient ischemic attack (TIA).
- Patients who have been diagnosed with malignancy (past or present) or primary haematological disorders.
- Patients who have renal impairment with serum creatinine more than 200 µmol/l or creatinine clearance less than 30 ml/min.
- Patients who have liver impairment with serum aspartate transaminase (AST) and alanine aminotransferase (ALT) two times greater than upper normal limit.
- Patients who are pregnant or are breastfeeding.
- Patients diagnosed with brain hemorrhage or other pathological brain disorders such as vascular malformation (brain arteriovenous malformation), tumor, abscess, cardiogenic, inflammatory and infectious cerebral embolism or other common non- ischemic brain diseases, or diagnosed with severe brain atrophy, as determined by CT or MRI scans.
- Patients diagnosed/suspected diagnosis with acute coronary syndrome.
- Patients with congestive cardiac failure.
- Patients with history of confirmed or suspected pulmonary embolism or chronic obstructive pulmonary disease (COPD).
- Patients with mental, cognitive or psychological disorders that affects their understanding and adherence to research procedures and follow-ups.
- Patients that are undergoing experimental drug or instrument testing or have participated in other clinical drug trials in the past 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control
Normal saline
|
Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.
|
Experimental: Neuroncell-EX
Umbilical cord-derived mesenchymal stem cells
|
Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Barthel Index (BI)
Time Frame: Baseline, 6 weeks, 3 months, 6 months and 12 months
|
Functional recovery after stroke onset is measured by the Barthel Index (BI).
BI score from 0-100, higher scores mean better outcome.
The investigators measure and compare the BI score for ischemic stroke patients who received Neuroncell-EX and control treatments.
|
Baseline, 6 weeks, 3 months, 6 months and 12 months
|
Modified Rankin Scale
Time Frame: Baseline, 6 weeks, 3 months, 6 months and 12 months
|
Functional recovery after stroke onset is measured by the modified Rankin Scale (mRS).
mRS is a 7 point (0-6) ranking scale to assess neurological disability.
A score of 0 indicates normal functions with no symptoms while higher scores indicates more severe neurological disability.The investigators measure and compare the mRS score for ischemic stroke patients who received Neuroncell-EX and control treatments.
|
Baseline, 6 weeks, 3 months, 6 months and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events due to umbilical cord-derived mesenchymal stem cells infusion as assessed by clinical examination.
Time Frame: Baseline, day 1, day 14, 6 weeks, 3 months, 6 months and 12 months
|
Presence or absence of any adverse events due to the umbilical cord-derived mesenchymal stem cells (UC-MSCs) infusion, sepsis, organ failure (clinically apparent or subclinical), hospitalization, cancers and death during the study period based on clinical examination.
|
Baseline, day 1, day 14, 6 weeks, 3 months, 6 months and 12 months
|
Survival and Re-admission rate
Time Frame: Baseline, day 1, day 14, 6 weeks, 3 months, 6 months and 12 months
|
Survival and re-admission rate
|
Baseline, day 1, day 14, 6 weeks, 3 months, 6 months and 12 months
|
Blood inflammatory markers before and after umbilical cord derived mesenchymal stem cell infusion based on subclinical analysis.
Time Frame: Baseline, 6 months and 12 months
|
Biomarkers concentration: Interleukin-6 (IL-6), interleukin-2 (IL-2), matrix metalloproteinase-9 (MMP-9), tumour necrosis factor alpha (TNFα), interleukin-1beta (IL-1β), vascular endothelial growth factor (VEGF), interleukin-10 (IL-10), Interleukin-1 receptor antagonist protein (IL-1Ra) and transforming growth factor beta 1 (TGF-β1).
|
Baseline, 6 months and 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Wan Nur Nafisah Wan Yahya, National University of Malaysia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- POD0031/CP/R
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Anaconda Biomed S.L.Not yet recruitingAcute Ischemic Stroke From Large Vessel Occlusion
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
Clinical Trials on Neuroncell-EX
-
University of Colorado, DenverCompletedOverweight and ObesityUnited States
-
Medtronic EndovascularWithdrawnPeripheral Arterial Disease
-
University Hospital, Clermont-FerrandLaboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques...Unknown
-
Wake Forest University Health SciencesCompletedObesity | Older Adults | SedentaryUnited States
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
St. Antonius Hospital GronauCompleted
-
Neuromed IRCCSRecruitingDrug Resistant EpilepsyItaly
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)CompletedObsessive-Compulsive DisorderUnited States
-
Asahi Kasei Medical Co., Ltd.Asahi Kasei Medical Europe GmbHTerminatedUlcerative ColitisUnited Kingdom, Japan, Germany, Sweden, Israel, Czech Republic